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Purpose: To report the one and two year outcome of cycles of three, monthly anti-VEGF
injections given upon reactivation of the disease in eyes with neovascular age-related
macular degeneration (nAMD).
Methods: Retrospective study of naïve nAMD cases with more than one year of follow-
up, treated with a protocol of cycles of three monthly injections of anti-VEGF drugs upon
reactivation. Visual acuity (VA) and central macular thickness (CMT) are the main outcome
measures.
Results: Twenty-six patients with a mean age of 78.15 ± 9.29 years (57.7% female)
were included. The mean follow-up was 30.89 ± 6.95 months. Treatment started with
bevacizumab in all patients but in six patients was switched to aflibercept due to inadequate
response to intravitreal bevacizumab injection. The mean VA at baseline and at 12 and 24
months was 53.87 ± 21.84, 60.54 ± 21.13, and 53.68 ± 27.16 ETDRS letters, respectively.
Patients gained a mean of 6.67± 13.7 (p = 0.013, 95% CI= 0.60 to 12.65) and 0.77±15.21 (p =
0.4, 95% CI: –5.65 to 7.2) letters at 12 and 24 months. CMT at baseline, 12, and 24 months
was 403.55 ± 147.59, 323.95 ± 79.58, and 298.59 ± 77.161 µm, respectively. The number of
injections in the first and second years were 7.65 ± 2.64 and 5.52 ± 3.01, respectively. Three
eyes (12.5%) lost >15 letters at 24 months.
Conclusion: This protocol can stabilize or improve vision in 87.5% of nAMD patients and can
reduce the number of visits.
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INTRODUCTION
Intravitreal injection of anti-VEGF drugs is currently
the standard treatment of the neovascular form
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of age-related macular degeneration (nAMD). The
randomized clinical trials that proved efficacy
of different anti-VEGF drugs administered
monthly or bimonthly intravitreal injections of
these medications.[1–3] However, fixed monthly
injections protocol seems to be a great burden in
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a real-world setting. Less than monthly protocols
have been examined; quarterly injections of
ranibizumab did not meet the non-inferiority
criteria compared to the monthly injections in PIER
and EXCITE studies.[4, 5] Pro-re-nata (PRN) dosing
based on pre-specified criteria of activity showed
more promising results.[6, 7] Treat and extend (T&E)
was another protocol first suggested by Spaide to
lessen the burden of injections and visits.[8] PRN
and T&E are among the most popular ones.[9]
In major randomized clinical trials of anti-VEGF
agents in nAMD, a loading dose of three monthly
injections has usually been applied followed by
fixed interval dosing protocol of injections.[1–3] As
a loading dose seems to be an accepted logic
for the initial suppression of choroidal neovascular
membrane (CNV) activity, it may also be more
effective than just one injection in reactivations of
CNV. Based on this logic, instead of giving just
one injection, we gave a cycle of three successive
monthly injections of anti-VEGF drugs with every
reactivation of the disease (PRN protocol). This
report is the visual and anatomic results at 12 and
24 months of using this protocol in the treatment of
naïve nAMD eyes.
METHODS
This is a retrospective study of naïve eyes with
nAMD treated with injection of anti-VEGF drugs in
cycles of three injections upon reactivation of the
disease. Data of patients who presented to one
of the three retina clinics of University of Texas
Medical Branch at Galveston (UTMB) from October
2014 to December 2016 and treated by a single
surgeon ( JE) were retrieved from the EMR of the
UTMB. The study was approved by the IRB and
followed the tenets of the Declaration of Helsinki.
Patients who were followed for more than one year
were included in this study. One eye per patient
was included and in case of bilateral AMD the first
involved eye was studied. There was no threshold
for the level of vision for inclusion in the study.
Patients had complete ophthalmic examination
including determination of best-corrected
visual acuity (BCVA) with the Snellen chart,
tonometry, slit lamp examination, and dilated
fundoscopy at presentation and at each follow-
up visit. Fluorescein angiography (FA) (HRA2,
Heidelberg Engineering, Germany) was performed
at presentation for all patients. Repeat FA
was at the discretion of the treating physician.
Optical coherence tomography (OCT) (Spectralis,
Heidelberg Engineering, Germany) was performed
at the initial and each follow-up visit.
Visual acuity (VA) was measured with Snellen
chart, and converted to ETDRS letters based on the
protocol previously described[10] with the formula:
approximate ETDRS letters = 85 + 50X log (Snellen
fraction). LogMAR VA was calculated and used for
comparison of the baseline and 12 and 24 months
data. VA of counting fingers was considered equal
to 1/200 or three letters of ETDRS chart.[11]
Anti-VEGF drugs used were aflibercept (Eylea;
Regeneron, Inc., Eastview, NY), bevacizumab
(Avastin; Genentech, Inc., South San Francisco,
CA), and ranibizumab (Lucentis; Genentech, Inc.,
South San Francisco, CA). All patients were started
with bevacizumab and in case of inadequate
response were switched to one of the other
two medications. The criteria for switching were:
<100 μm reduction in central macular thickness
(CMT), worsening, or no significant changes in the
amount of subretinal/intraretinal fluid after three
monthly injections of bevacizumab, or persistence
of subretinal/intraretinal fluid after six monthly
injections of bevacizumab. Injection sessions were
separate from visit sessions due to the process
needed for provision of the medicine.
Protocol
At the commencement of treatment and upon
discovery of disease activity at any visit, patients
were treated with three monthly doses of anti-
VEGF drugs. Follow-up examinations after each
series of injections were scheduled monthly for
the first two months; extended to bimonthly and
after two bimonthly visits to every three months
and continued as such if there was no activity of
the disease. Patients were also instructed to check
their central vision at home and return promptly
in case of any new metamorphopsia, scotoma,
or change in vision. Disease activity was judged
based on the presence or absence of intraretinal
or subretinal fluid in OCT scans, or the presence of
intraretinal or subretinal blood on fundoscopy.
Statistical Analysis
Descriptive statistics are provided as mean ±SD,
median (25–75 quartiles) or percentage. VA and
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central foveal thickness data were analyzed with
the Shapiro–Wilk test and their distribution was
found not to be normal, so a comparison of vision
or central foveal thickness results were made
by Wilcoxon signed rank test. P-value < 0.05
was considered significant. Statistical analysis was
performed by Statistical Package for Social Studies
(SPSS) version 25 (IBM Inc., Armonk, NY).
RESULTS
Twenty six patients with a mean age of 78.15 ±
9.29 years (57.7% female) were included. Themean
follow-up was 30.89 ± 6.95 months. All patients
were started with bevacizumab injections (off label
use), six were subsequently switched after a mean
of nine injections to aflibercept. Second time
switching to ranibizumab was performed in one
patient. Twenty three (88.46%) patients completed
two years of follow-up. One patient did not have
complete follow-up of two years. One patient was
lost to follow-up in the second year. Patients missed
their appointments (either injection or non-injection
visits) for more than one month in two cases during
the first year (1.5 and 2 months of delay) and in four
cases during the second year (2 ± 1 months).
VA at baseline was from 3 to 80 ETDRS letters
with a mean of 53.87 ± 21.84 letters (0.65 ±
0.51 logMAR). Six (23.08%) patients had a vision
of >20/40 (70 ETDRS letters) and eight (30.77%)
≤20/200 (35 ETDRS letters) at presentation.
The range of VA at 12 months was 3 to 85 with a
mean of 60.54 ± 21.13 ETDRS letters (0.51 ± 0.51
logMAR) significantly different from the baseline
vision (p = 0.013). Twelve eyes (46.15%) had a vision
of >20/40 and four (15.38%) ≤20/200 at 12 months.
The range of VA at 24 months was 0 to 85 with
a mean of 53.68 ± 27.16 ETDRS letters (0.68 ± 0.67
logMAR), which was not different from baseline (p
= 0.4). Eleven (45.83%) patients had a vision of
>20/40 and six (25%) ≤20/200 at 24 months.
Patients gained a mean of 6.67± 13.7 (95% CI =
0.60 to 12.65) letters at 12 months, which equals
to a mean logMAR change of –0.14 ± 0.36. At
24 months, patients gained a mean of 0.77 ±15.21
(95% CI: –5.65 to 7.2) letters compared to baseline
which equals to a mean change in logMAR of –0.01
± 0.38. The number of patients with gain and loss
of vision are provided in Table 1.
Changes in logMAR VA and CMT are presented
in Figure 1.
Of the six patients with baseline VA of 20/40 or
more (70 ETDRS letters), all had a vision of 20/40
or more at 12 months. Only one eye had a vision
of <20/40 at 24 months. There were a total of 10
eyes (38.46%) at 12 months and 9 eyes (37.5%) at
24 months with a vision of 20/40 or more.
Of the eight patients with baseline VA of 20/200
or less (35 ETDRS letters), four in the first year and
five in the second retained the vision of <20/200.
There were a total of four (15.38%) eyes at 12
months and six (25%) eyes at 24 months with a
vision of 20/200 or less. Of the six cases with a
vision of 20/200 or less at 24 months, only one
case had a better vision at baseline.
The mean CMT at baseline, 12, and 24 months
was 403.55 ± 147.59, 323.95 ± 79.58, and 298.59
± 77.161 µm, respectively [Figure 1]. There was
a reduction of CMT relative to baseline of –
88.24 ± 148.41 µm in the first year (p = 0.013,
95% CI = –164.81 to –14.77) and –103.16 ± 108.61
(p < 0.001, 95% CI = –155.50 to –50.81) µm
in the second year. OCT was fluid free at 12-
and 24-months encounters in 52% and 72.7%
of eyes, respectively. Seven and eight eyes had
intraretinal and subretinal fluid at the 12 months’
visit, respectively. These numbers were 6 and 1
for the 24 months’ and 6 and 3 for the last visits,
respectively. Patients received a mean of 7.65 ±
2.64 injections in the first year and 5.52 ± 3.01
injections in second. The mean total number of
injections over 24 months was 15 ± 6.9 given in a
mean of 4.85 ± 2.18 cycles. The total number of
non-injection visits was 4.92 ± 1.55 during the first
year and 5.04 ± 1.46 during the second.
Seven patients (27%) achieved long-term
periods of inactivity of >12 months (mean, 16.93,
range, 14.5–22 months) which started in year 1 and
extended into year 2. The longest injection-free
period for the remaining patients was 2.95 ± 2.8
(0 to 8.00) months in the first year and 3.65 ± 2.35
(0-8.00) months in the second.
All patients were first treated with bevacizumab
and six of them were switched to aflibercept after a
mean of nine injections; one was further switched
to ranibizumab, so we can consider them to be
practically treated with bevacizumab during the
first year. Of the total of seven switching episodes
in six eyes, vision improved in three eyes (13.25
± 7.68 letters), remained stable in three, and
worsened in one after one cycle of treatment with
the new medication, and fluid in OCT improved in
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Figure 1. Changes in logMAR visual acuity and central macular thickness at baseline and 12 and 24 months.
five cases, and remained stable in two after one
cycle of treatment.
Injections were discontinued in three eyes in the
second year due to the development of central
geographic atrophy or futility of treatment.
DISCUSSION
Intravitreal injections of anti-VEGF drugs in cycles
of three injections on a PRN basis in naïve
neovascular AMD cases resulted in a visual gain of
6.67 letters at 12months and a gain of 0.77 letters at
24 months. The visual results at one year are better
than most real-world studies and the 24 months’
results are comparable.[12–14]
Although clinical trials that proved efficacy of
intravitreal injection of anti-VEGF drugs reported
vision gains of 6.5–11.3 letters in the first and
second years,[1–3] real-world studies have not
corroborated those results.[12–14] In routine clinical
practice as opposed to clinical trials, injections are
usually given based on a variable dosing schedule
rather than monthly,[9] treatment is offered to
all presenting with the disease and patients are
not selected to fulfill certain VA, lesion size, or
composition criteria. Another important difference
is complying with the follow-up visits which are
not as accurately followed by the patients and
physicians as in a predesigned clinical trial. Many
studies have explored the cause for inferior
results in the real-world setting. While some
have found no or weak correlations between the
number of injections and visual results,[7, 14] others
believe that there is a correlation between the
number of injections and visual gain, especially
when the number of injections falls <5–6 per
year, the visual results get worse.[13, 15–18] Use
of variable dosing regimens instead of monthly
injections is another area of debate. Although
major clinical trials such as CATT and IVAN
have provided proof to the similarity of results
between monthly and PRN dosing in the first
year, visual results differ in favor of monthly
treatment after two years (–2.4 letters difference,
95% CI, –4.8 to –0.1; P = 0.046, CATT trial).[19–21]
Contribution of all the aforementioned factors
results in real-world treatment to be mostly
preventive of further visual deterioration instead
of increasing vision as expected by results
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Table 1. The number of patients with gain or loss of vision at 12 and 24 months
12 months 24 months
Gain of >15 letters 12 (46.15%) 8 (33.33%)
Gain of >5 letters 13 (50%) 11 (45.83%)
<5 letters change 9 (34.61%) 7 (29.16%)
Loss of >5 letters 4 (15.38%) 6 (25%)
Loss of >15 letters 1 (4%) 3 (12.5%)
of clinical trials.[12–14] Physicians have devised
newer strategies to improve the results in routine
clinical practice, such as the “observe and plan”
protocol.[22, 23] Reports of observe and plan
protocol seem very promising, however, results
are still not available in a real-world setting,
besides the protocol seems too complicated
to be followed thoroughly in a routine clinical
practice.
In nearly all major RCTs of anti-VEGF agents and
also in clinical practice, treatment is started with
a loading dose of three monthly injections,[3, 6, 24]
which has been shown to result in better visual
outcomes compared to PRN dosing from the
outset.[25] We speculate that for an active CNV,
there is a need for continuous suppression of VEGF
for at least three months until the CNV becomes
quiescent andwe generalized this concept to every
reactivation, so we treated every reactivation of
the disease with another three monthly series
of injections with the hope that adoption of
this strategy within an as-needed protocol may
improve the results by replacing some of the non-
injection visits with injection visits. This is similar
to the protocol used in the IVAN study.[20, 21] The
difference between our and IVAN’s protocols is
in the follow-up visits, which were kept monthly
in the IVAN study but were extended upon
inactivity in two successive visits in the current
study, that is, incorporation of a T&E philosophy
within the PRN protocol. Another major difference
of the current study with IVAN is that IVAN
was a prospective randomized controlled clinical
trial, whereas this study is a retrospective real-
world description of the results of the protocol.
In spite of being a real-world study, the results
of this study compare to those of IVAN [Table
2].
PRN treatment of AMDwith anti-VEGF drugs was
first examined in the PrONTO study, which was
not a controlled study, and reported visual results
comparable to the results of MARINA and ANCHOR
trials. In this prospective study, patients with nAMD
were treated based on visual, angiographic, and
OCT objective criteria of reactivation. The study
followed a strict monthly follow-up of patients
and treatment was started with three monthly
injections followed by an as-needed treatment.
There was a +9.3 (11 median) letter improvement
in the first year and 11.1 ± 12.2 letter improvement
in the second. The authors of PrONTO study
conclude that their results are similar to the
pivotal phase III trials with lower number of
injections.[6, 7]
PRN treatment was compared with monthly
regimens in some prominent RCTs. For example,
in CATT study, monthly and PRN treatment of
ranibizumab had a comparable visual results
at 12 months. Analysis was inconclusive for
bevacizumab monthly versus as needed in that
trial. Worse visual results were reported at 24
months for eyes receiving PRN treatment of
either ranibizumab or bevacizumab (–2.4 letters
difference, 95% CI, –4.8 to –0.1; P = 0.046).[19, 26]
IVAN study similarly showed that the difference
in visual gain at 12 and 24 months was neither
non-inferior nor inferior in PRN treatment when
compared to monthly treatment.[20, 21]
The results of T&E protocol are even more
promising.[27, 28] In a long-term study of the T&E
protocol, Berg et al[29] reported a visual gain of
6.1 letters in the first year and >7.4 letters up to
four years after the initiation of the treatment in
a real-world setting. In a meta-analysis of real-
world studies, T&E protocol had a better visual
results than PRN treatment with +8.5 versus +3.5
letters improvement in the first year and +6.7
versus +1.3 letters in the second, respectively.[30]
Systematic reviews have also shown better results
with T&E protocol compared to PRN dosing.[27, 28]
Comparison of the PRN and T&E protocols in real-
world studies have provided similar results.[31–33]
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In the routine clinical practice, physicians mostly
use the PRN or T&E protocols for the treatment of
nAMD,[9] so the real-world studies reported based
on electronic databases usually include patients
treated by these two protocols in practice. In
spite of the promising results of clinical trials, and
aforementioned studies, visual results of real-world
studies are not very impressive. Rao et al[14] in
a real-world study of intravitreal injection of anti-
VEGF drugs for the treatment of AMD in the US,
based on data from the Intelligent Research in Sight
(IRIS) registry, compared the one-year outcomes
of the injections of bevacizumab, ranibizumab,
and aflibercept. Patients gained –0.04 to –0.053
logMAR in the first 12 months with a mean of
5.9–6.4 injections of bevacizumab, ranibizumab, or
aflibercept. Similarly, Ciulla et al[13] reporting results
from Vestrum Health Retina Database from the
US stated that there was no change of vision (–
0.7 ETDRS letters, p = 0.43) at 12 months with 7.3
injections of the three drugs. Lotery et al[12] found a
change of−0.30± 14.8 and−0.19± 14.7 letters with
6.7–7 injections of ranibizumab and aflibercept,
respectively, at 12 months in cases retrieved form
a standard EMR in the US.
Although different studies cannot be directly
compared with each other, with a mean gain
of 6.67 ± 13.7 ETDRS letters at 12 months and
0.77 ± 15.21 at 24 months, results of the current
study seem to be better than the results of
most real-world studies in the US and compares
to the results of the IVAN trial, which was a
prospective study [Table 2]. Having similar results
at 12 and 24 months to a prospective study
is promising. As irregular follow-ups can be a
cause of poor visual outcomes in the real-world
studies, having few missed appointments in this
study may discuss the similarity of results with
a prospective study. However, in the current
study, the follow-ups were extended to three
months, mostly in the second year, while in the
IVAN study, monthly follow-ups were pursued
through the second year. Undertreatment has been
stated as an important factor causing lower visual
results in real-world settings.[13] The number of
injections in the first and second years in the
current study was 7.65 ± 2.64 and 5.52 ± 3.01,
respectively, for a cumulative number of 15 ±
6.9 during the two years. This number compares
with both the real-world studies and the PRN
groups of IVAN, CATT, and PrONTO studies [Table
2].
The number of non-injection visits in the first
and second years was 4.92 ± 1.55 and 5.04 ±
1.46, respectively. The current study was performed
where bevacizumab would usually be injected in a
separate visit because of logistics in preparation of
the medication. If same-day injection was possible,
the number of non-injection visits would certainly
be lower than the current results. We also believe
that with the aforementioned situation, this protocol
of PRN cycles of injections has saved patients
many unnecessary visits. Also, the PRN nature of
decision-making has spared patients from many
injections. Indeed, 27% of patients in this study
achieved inactivity of the disease for 14–22months
without injections.
In the current study, OCT was fluid-free in 52%
and 72.7% at 12 and 24 months, respectively. The
corresponding rates in the IVAN study were 31 and
37% in the discontinuous treatment group.[20, 21]
In CATT study, 19 and 13.9% of eyes in the PRN
bevacizumab group and 23.9 and 22.3% of eyes
in the PRN ranibizumab group were without any
fluid in OCT at 12 and 24 months, respectively.[19, 26]
The monthly treatment groups of both IVAN and
CATT had higher rates of absence of fluid in
OCT at 12 and 24 months: 44 and 54% for the
continuous treatment group – IVAN study; 26 and
30.2% in the bevacizumab monthly – CATT study;
and 43.7 and 45.5% for ranibizumab monthly –
CATT study. In a study by Hatz et al,[32] which
was a prospective study comparing the T&E and
PRN protocols, the rate of absence of any fluid
in OCT at 12 months was 67% in the T&E and
47% in the PRN group. The results of our study
seem to be comparable to the results of this study,
sitting somewhere between the PRN and T&E
groups.
There is a worse visual outcome in the second
year in spite of less activity of the disease in OCT
[Figure 1]. As we did not restrict inclusion of patients
based on VA levels, lesion size, or components,
it is possible that the development of atrophy or
scar in eyes with more advanced lesions during the
second year of the study have skewed the results
toward lower vision range.
This study is a retrospective study and limitations
of retrospective studies apply to it. One of the
major limitations is that VA is not measured by
the ETDRS chart and is reported as approximate
ETDRS letters which is a calculated number. Some
real-world studies have provided that patients who
are lost to follow-up have worse vision at their
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last visit compared to those who are followed-
up.[13, 17, 34, 35] Thus, by not including patients lost to
follow-up before one year, we may have introduced
a selection bias toward patients with better visual
results. The small number of patients is another
limitation of the current study. As previously
stated, because of the unavailability of same-day
injections, the number of non-injection visits may
have been overestimated.
In conclusion, the visual results of the current
study in the first year are very promising. The
protocol is easy to implement and the compliance
rate is very high. In the second year of the study,
there is a decrease in the gained letters of VA in
spite of a higher rate of inactivity of the lesions in
OCT. Continuing monthly follow-ups may reduce
the vision loss in the second year.
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